Invasive Pulmonary Aspergillosis (IPA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Invasive pulmonary aspergillosis (IPA) Market Outlook and Forecast

Invasive Pulmonary Aspergillosis (IPA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Published Date : 2021-11-20

Updated On : 2023-09-28

Pages : 153

Invasive Pulmonary Aspergillosis (IPA) Market Outlook

Thelansis’s “Invasive Pulmonary Aspergillosis (IPA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Invasive Pulmonary Aspergillosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Invasive Pulmonary Aspergillosis (IPA) Overview

Invasive pulmonary aspergillosis (IPA) is a severe fungal infection associated with a high mortality rate. The incidence of IPA is on the rise, primarily due to the increasing number of patients undergoing transplants, receiving chemotherapy, and undergoing immunosuppressive therapy. Invasive pulmonary aspergillosis typically manifests in two distinct scenarios:

  1. The classic form of invasive pulmonary aspergillosis occurs as primary pneumonia in patients with profound immunosuppression, such as prolonged neutropenia. This particular presentation has been recognized for many years.
  2. Another common scenario is secondary nosocomial pneumonia, which affects patients admitted to the ICU for other reasons, like ARDS caused by influenza. It is a challenging diagnosis because critically ill patients with superinfections of aspergillus are not usually profoundly immunosuppressed. This superinfection can closely resemble bacterial pneumonia or ARDS and may be overshadowed by the patient's other medical issues.

The diagnosis of IPA is complicated due to the non-specific nature of its symptoms. The mainstay of therapy for IPA is Voriconazole. This condition primarily affects severely immunocompromised individuals, including those with prolonged neutropenia resulting from chemotherapy, immunosuppressive therapy, post-hematopoietic stem cell transplant (SCT), or solid organ transplant. When evaluating a child with a cystic or cavitary lung lesion, the list of potential causes is extensive and includes both congenital and acquired lung abnormalities. Congenital cystic lesions include lobar emphysema, cystic adenomatoid malformations, pleuropulmonary blastoma, bronchogenic cysts, and pulmonary sequestration. Acquired lung lesions are categorized as infectious, neoplastic, or stemming from miscellaneous causes. Bacterial and fungal infections predominate among the common infectious causes, while parasitic infestations like paragonimiasis and hydatidosis are rare outside of endemic regions. Pulmonary cysts or pneumatoceles are most commonly associated with organisms such as Staphylococcus, Pseudomonas, Klebsiella, and anaerobes. Lung abscesses can be caused by gram-negative bacteria, anaerobes, and occasionally Staphylococcus.

  • The overall one-year mortality rate for IPA is 32%. Specifically, patients with COVID-19 in the ICU have the highest one-year mortality rate, followed by those with acute myeloid leukemia and aplastic anemia, with mortality rates of 54%, 50%, and 39%, respectively.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages:
Linkedin Mini logo Thelansis Twitter Mini logoThelansis Facebook Mini logo

Invasive Pulmonary Aspergillosis (IPA) Competitive Landscape

S. no Asset Company Stage
1 SCY-078 and Voriconazole Scynexis, Inc. Phase 2
2 PC945 Pulmocide Ltd Phase 3
3 Posaconazole and Voriconazole Merck Sharp & Dohme LLC Phase 3

KOLs across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

COUNTRY No. Of KOLs
USA 17
GERMANY 4
UK 4
SPAIN 3
FRANCE 2
ITALY 3
JAPAN 3
CHINA 4

Invasive Pulmonary Aspergillosis (IPA) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

Data Inputs with sourcing, Market Event, Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Invasive pulmonary aspergillosis (IPA) Market Forecast

1.       Invasive Pulmonary Aspergillosis (IPA) – Key Findings Summary

         1.1.    Clinical findings
                     1.1.1. Disease overview
                     1.1.2. Therapeutic practices
                     1.1.3. Future outlook
         1.2.    Commercial findings
                     1.2.1. Invasive Pulmonary Aspergillosis (IPA) market scenario 2021
                     1.2.2. Invasive Pulmonary Aspergillosis (IPA) market scenario 2025
                     1.2.3. Invasive Pulmonary Aspergillosis (IPA) market scenario 2032

2.       Invasive Pulmonary Aspergillosis (IPA) Overview

         2.1.    Disease Introduction
         2.2.    Pathophysiology
         2.3.    Signs and Symptoms
         2.4.    Risk Factors
         2.5.    Etiology
         2.6.    Classification
         2.7.    Pathogenesis
         2.8.    Diagnosis
         2.9.    Complications
         2.10. Treatment Algorithm
                     2.10.1.    Treatment in US (guidelines)
                     2.10.2.    Treatment in EU-5 (guidelines)
                     2.10.3.    Treatment in Japan (guidelines)
                     2.10.4.    Treatment in China (guidelines)
         2.11. Treatment Goals for Invasive Pulmonary Aspergillosis (IPA)
         2.12. Referral Patterns
                     2.12.1.    Referral Scenario in US
                     2.12.2.    Referral Scenario in EU-5
                     2.12.3.    Referral Scenario in Japan
                     2.12.4.    Referral Scenario in China
         2.13. Invasive Pulmonary Aspergillosis (IPA) Prognosis
         2.14. Healthcare burden
                     2.14.1.    Healthcare burden in US
                     2.14.2.    Healthcare burden in EU-5
                     2.14.3.    Healthcare burden in Japan
                     2.14.4.    Healthcare burden in China
         2.15.  Unmet Needs in Invasive Pulmonary Aspergillosis (IPA) management
         2.16.  Market Opportunity for Invasive Pulmonary Aspergillosis (IPA)
         2.17. KOL Comments on current and upcoming/expected treatment practices in Invasive Pulmonary Aspergillosis (IPA)

3.       Epidemiology

         3.1.    Epidemiology Overview
         3.2.    Epidemiology by Geography
                     3.2.1.  Invasive Pulmonary Aspergillosis (IPA) Epidemiology in US (2021-2032)
                             3.2.1.1.              Incidence of Invasive Pulmonary Aspergillosis (IPA)
                             3.2.1.2.              Diagnosed cases
                             3.2.1.3.              Treatable Patient Pool
                             3.2.1.4.              Epidemiology Trends
                     3.2.2.  Invasive Pulmonary Aspergillosis (IPA) Epidemiology in EU-5 (2021-2032)
                             3.2.2.1.              Incidence of Invasive Pulmonary Aspergillosis (IPA)
                             3.2.2.2.              Diagnosed cases
                             3.2.2.3.              Treatable Patient Pool
                             3.2.2.4.              Epidemiology Trends
                     3.2.3.  Invasive Pulmonary Aspergillosis (IPA) Epidemiology in Japan (2021-2032)
                             3.2.3.1.              Incidence of Invasive Pulmonary Aspergillosis (IPA)
                             3.2.3.2.              Diagnosed cases
                             3.2.3.3.              Treatable Patient Pool
                             3.2.3.4.              Epidemiology Trends
                     3.2.4.  Invasive Pulmonary Aspergillosis (IPA) Epidemiology in China (2021-2032)
                             3.2.4.1.              Incidence of Invasive Pulmonary Aspergillosis (IPA)
                             3.2.4.2.              Diagnosed cases
                             3.2.4.3.              Treatable Patient Pool
                             3.2.4.4.              Epidemiology Trends
         3.3.    Epidemiology Trends (World-wide)

4.       Market Outlook

         4.1.    US Invasive Pulmonary Aspergillosis (IPA) Market Forecast 2021-2032
                     4.1.1. Market Progression (Futuristic)
                     4.1.2. Market Trends and Expectations
                             4.1.2.1.              Worst case scenario
                             4.1.2.2.              Base Case Scenario
                             4.1.2.3.              Best Case Scenario
                     4.1.3. Drivers and Barriers
         4.2.    UK Invasive Pulmonary Aspergillosis (IPA) Market Forecast 2021-2032
                     4.2.1. Market Progression (Futuristic)
                     4.2.2. Market Trends and Expectations
                             4.2.2.1.              Worst case scenario
                             4.2.2.2.              Base Case Scenario
                             4.2.2.3.              Best Case Scenario
                     4.2.3. Drivers and Barriers
         4.3.    France Invasive Pulmonary Aspergillosis (IPA) Market Forecast 2021-2032
                     4.3.1. Market Progression (Futuristic)
                     4.3.2. Market Trends and Expectations
                             4.3.2.1.              Worst case scenario
                             4.3.2.2.              Base Case Scenario
                             4.3.2.3.              Best Case Scenario
                     4.3.3. Drivers and Barriers
         4.4.    Germany Invasive Pulmonary Aspergillosis (IPA) Market Forecast 2021-2032
                     4.4.1. Market Progression (Futuristic)
                     4.4.2. Market Trends and Expectations
                             4.4.2.1.              Worst case scenario
                             4.4.2.2.              Base Case Scenario
                             4.4.2.3.              Best Case Scenario
                     4.4.3. Drivers and Barriers
         4.5.    Italy Invasive Pulmonary Aspergillosis (IPA) Market Forecast 2021-2032
                     4.5.1. Market Progression (Futuristic)
                     4.5.2. Market Trends and Expectations
                             4.5.2.1.              Worst case scenario
                             4.5.2.2.              Base Case Scenario
                             4.5.2.3.              Best Case Scenario
                     4.5.3. Drivers and Barriers
         4.6.    Spain Invasive Pulmonary Aspergillosis (IPA) Market Forecast 2021-2032
                     4.6.1. Market Progression (Futuristic)
                     4.6.2. Market Trends and Expectations
                             4.6.2.1.              Worst case scenario
                             4.6.2.2.              Base Case Scenario
                             4.6.2.3.              Best Case Scenario
                     4.6.3. Drivers and Barriers
         4.7.    Japan Invasive Pulmonary Aspergillosis (IPA) Market Forecast 2021-2032
                     4.7.1. Market Progression (Futuristic)
                     4.7.2. Market Trends and Expectations
                             4.7.2.1.              Worst case scenario
                             4.7.2.2.              Base Case Scenario
                             4.7.2.3.              Best Case Scenario
                     4.7.3. Drivers and Barriers
         4.8.    China Invasive Pulmonary Aspergillosis (IPA) Market Forecast 2021-2032
                     4.8.1. Market Progression (Futuristic)
                     4.8.2. Market Trends and Expectations
                             4.8.2.1.              Worst case scenario
                             4.8.2.2.              Base Case Scenario
                             4.8.2.3.              Best Case Scenario
                     4.8.3. Drivers and Barriers
         4.9.    Key Expected Milestones (world-wide) Impacting the Market

5.       Competitive Landscape

         5.1.    Pipeline Therapies Overview
                     5.1.1. Phase III Therapies
                                      5.1.1.1.                     Current Status
                                      5.1.1.2.                     Trial details, results
                                      5.1.1.3.                     Approval Timeline
                                      5.1.1.4.                     Likelihood of approval
                                      5.1.1.5.                     Expected Product Positioning
                             5.1.1.2.              All other Phase III Therapies …..
                             5.1.1.3.              Attribute Analysis of Phase III molecules
                     5.1.2.  Phase II and Phase I/II Therapies
                                      5.1.2.1.                     Current Status
                                      5.1.2.2.                     Trial details, results
                                      5.1.2.3.                     Approval Timelines
                     5.1.3. List of active Pre-clinical Therapies
                                      5.1.3.1.                     Status in Invasive Pulmonary Aspergillosis (IPA)
                                      5.1.3.2.                     Company positioning
                             5.1.3.2.              All other pre-clinical therapies
                     5.1.4. List of Inactive/discontinued assets
                             5.1.4.1.              Business impact of discontinuations on current pipeline
                     5.1.5. Potential winners from Invasive Pulmonary Aspergillosis (IPA) Pipeline
                             5.1.5.1.              Potential Blockbusters across the pipeline

6.       Regulatory/Approval Scenario

         6.1.    Regulatory/Approval Framework in US
                     6.1.1. Policy Framework
                     6.1.2. Payer Expectations
         6.2.    Regulatory/Approval Framework in UK
                     6.2.1. Policy Framework
                     6.2.2. Payer Expectations
         6.3.    Regulatory/Approval Framework in France
                     6.3.1. Policy Framework
                     6.3.2. Payer Expectations
         6.4.    Regulatory/Approval Framework in Germany
                     6.4.1. Policy Framework
                     6.4.2. Payer Expectations
         6.5.    Regulatory/Approval Framework in Italy
                     6.5.1. Policy Framework
                     6.5.2. Payer Expectations
         6.6.    Regulatory/Approval Framework in Spain
                     6.6.1. Policy Framework
                     6.6.2. Payer Expectations
         6.7.       Regulatory/Approval Framework in Japan
                     6.7.1. Policy Framework
                     6.7.2. Payer Expectations
         6.8.       Regulatory/Approval Framework in China
                     6.8.1. Policy Framework
                     6.8.2. Payer Expectations

7.       Clinical Trial Assessment – Current and Future Paradigm

         7.1.    Distribution of Primary Endpoints across trials
         7.2.    Distribution of Secondary Endpoints across trials
         7.3.    Evolution and acceptance of surrogate endpoints
         7.4.    Key Investigator initiated trials
         7.5.    Attrition analysis
                     7.5.1. Suspended/Discontinued Assets
                     7.5.2. Failed Trials, Reasons and Business Impact
                     7.5.3. Terminated Trials, Reasons and Business Impact
                     7.5.4. Withdrawn Trials, Reasons and Business Impact
         7.6.    Trial enrollment scenario and challenges
         7.7.    Clinical Trial Guidance (across geographies)

8.       Thelansis Commentary

         8.1.    Key Unmet needs in Invasive Pulmonary Aspergillosis (IPA)
         8.2.    Possible Best-case Clinical Trial Strategies
         8.3.    Possible Best Case Targeted Product Profile (TPP)
         8.4.    Possible Best-case Market positioning strategies
         8.5.    Possible Best-case Market Access Strategies
         8.6.    Possible Best-case LCM Strategies
         8.7.    Overall View on Invasive Pulmonary Aspergillosis (IPA) Market in Dollar Value

9.       Report Methodology

         9.1.    Secondary research
         9.2.    Primary research
         9.3.    Data collation
         9.4.    Insight Generation

10.   About Thelansis

         10.1.    Our Capabilities
         10.2.    Our Services
         10.3.    Our Contacts
         10.4.    Disclaimer